Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$381K Buy
3,358
+93
+3% +$9.22K ﹤0.01% 593
2026
Q1
$307K Buy
3,265
+13
+0.4% +$1.3K ﹤0.01% 647
2025
Q4
$321K Buy
3,252
+372
+13% +$36K ﹤0.01% 627
2025
Q3
$244K Sell
2,880
-171
-6% -$13.5K ﹤0.01% 715
2025
Q2
$208K Sell
3,051
-2,001
-40% -$127K ﹤0.01% 756
2025
Q1
$306K Sell
5,052
-14
-0.3% -$976 ﹤0.01% 638
2024
Q4
$350K Buy
5,066
+217
+4% +$15.5K ﹤0.01% 605
2024
Q3
$321K Sell
4,849
-21
-0.4% -$1.34K ﹤0.01% 643
2024
Q2
$295K Buy
+4,870
New +$276K ﹤0.01% 628
2023
Q1
Sell
-2,683
Closed -$215K 781
2022
Q4
$215K Buy
+2,683
New +$205K ﹤0.01% 683
2018
Q1
Sell
-131
Closed -$12K 595
2017
Q4
$12K Hold
131
﹤0.01% 649
2017
Q3
$15K Buy
+131
New +$16.6K ﹤0.01% 621

Other funds holding INCY

Greenleaf Trust's INCY Position: Q2 2026 in Review

Greenleaf Trust increased its Incyte (INCY) stake by 2.8% in Q2 2026, buying an estimated $9.22K and bringing the position to 3,358 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Greenleaf Trust first reported a position in INCY in Q3 2017 and has held it in 12 quarters since. 859 funds tracked by Wall St. Rank hold INCY as of Q2 2026.

  • Greenleaf Trust held 3,358 shares of Incyte worth $381K as of Q2 2026.
  • Greenleaf Trust bought 93 Incyte shares in Q2 2026, an estimated $9.22K.
  • Incyte made up ﹤0.01% of Greenleaf Trust's portfolio in Q2 2026, its #593 holding.
  • Greenleaf Trust first reported a position in Incyte in Q3 2017 and has held it in 12 quarters since.
  • 859 funds tracked by Wall St. Rank held Incyte as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.